T. Delozier

Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

C. Focan, S. M. Steinberg, M Blichert-Toft et al. · PubMed · 1998 · 2.2K citations

Medicine, Oncology, Pharmacotherapy +5

A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer

R. Charles Coombes, Emma Hall, Lorna J. Gibson et al. · New England Journal of Medicine · 2004 · 1.8K citations · Full text

Pharmacy, Endocrinology, Oncology +13

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

Javier Cortés, Joyce O’Shaughnessy, David Loesch et al. · The Lancet · 2011 · 1.1K citations

Medicine, Oncology, Pharmacotherapy +9

Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

R. Charles Coombes, CF Snowdon, Robert Paridaens et al. · The Lancet · 2007 · 909 citations

Medicine, Endocrinology, Oncology +4

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

David Miles, Arlene Chan, Luc Dirix et al. · Journal of Clinical Oncology · 2010 · 887 citations

Medicine, Oncology, Pharmacology +17